Treatment of Bowel Syndrome with Constipation: An Experience with The Agonist of Guanylate Cyclase Receptor in Advanced Age Patients

Abstract

Background Irritable bowel syndrome is a very common condition in the elderly, and it can also be extremely disabling being able to go to undermine the patient's independence. We wanted to conduct a study on the Territory to test a recently approved molecule for treating a variant with constipation-predominant irritable bowel syndrome, testing the treatment in a cohort of elderly subjects and comparing the results with those of other existing therapies. Here we exposed the results of our experience. Material and Methods We conducted an open-label study in the general medicine setting, enrolling patients who appeared eligible for drug treatment with the study drug during the medical examination. So we examined 20 elderly patients. Half of the patients were treated with linaclotide 290 mcg, the other 50% with macrogol 27.6 g (25%) and psyllium 2 sachets/day (25%), continuing the treatment up to 12 weeks. Results There was a reduction of bloating in 70% of the Linaclotide group and 80% of the macrogol and psyllium group, an improvement/reduction of tenesmus in 100% of patients in the three groups, with a change in the quality of stool occurring with Bristol Stool Scale assessment. 60% of patients failed to complete therapy in 3 months. Conclusions Linaclotide is an innovative drug increasingly gaining space in the pharmacopoeia in the possession of doctors for treating intestinal disorders on a functional basis. The limited experience has shown little tolerance of Linaclotide compared to treatments for longer in force, especially in the elderly.

Keywords

• Irritable bowel syndrome
• constipation
• pharmacologic therapies
• guanylate cyclase-C receptor
• elderly patient

References

1. Torii A, Toda G. Management of irritable bowel syndrome. Intern Med. 2004 May;43(5):353-9. doi: 10.2169/internalmedicine.43.353.
2. Rubin G, De Wit N, Meineche-Schmidt V, Seifert B, Hall N, Hungin P. The diagnosis of IBS in primary care: consensus development using nominal group technique. Fam Pract. 2006 Dec;23(6):687-92. doi: 10.1093/fampra/cml050.
3. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003 Mar 1;17(5):643-50. doi: 10.1046/j.1365-2036.2003.01456.x.
4. Doshi JA, Cai Q, Buono JL, Spalding WM, Sarocco P, Tan H, Stephenson JJ, Carson RT. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. J Manag Care Spec Pharm. 2014 Apr;20(4):382-90. doi: 10.18553/jmcp.2014.20.4.382.
5. Mayer EA. Clinical practice. Irritable bowel syndrome. N Engl J Med. 2008 Apr 17;358(16):1692-9. doi: 10.1056/NEJMcp0801447.
6. Lazaraki G, Chatzimavroudis G, Katsinelos P. Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol. 2014 Jul 21;20(27):8867-85. doi: 10.3748/wjg.v20.i27.8867.
7. Maneerattanaporn M, Chang L, Chey WD. Emerging pharmacological therapies for the irritable bowel syndrome. Gastroenterol Clin North Am. 2011 Mar;40(1):223-43. doi: 10.1016/j.gtc.2010.12.002.
8. Yu SW, Rao SS. Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide. Therap Adv Gastroenterol. 2014 Sep;7(5):193-205. doi: 10.1177/1756283X14537882.

9. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P; Clinical Services Committee of The British Society of Gastroenterology. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007 Dec;56(12):1770-98. doi: 10.1136/gut.2007.119446.
10. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006 Apr;130(5):1480-91. doi: 10.1053/j.gastro.2005.11.061.
11. Malagelada JR. A symptom-based approach to making a positive diagnosis of irritable bowel syndrome with constipation. Int J Clin Pract. 2006 Jan;60(1):57-63. doi: 10.1111/j.1368-5031.2005.00744.x.
12. Jeong H, Lee HR, Yoo BC, Park SM. Manning criteria in irritable bowel syndrome: its diagnostic significance. Korean J Intern Med. 1993 Jan;8(1):34-9. doi: 10.3904/kjim.1993.8.1.34.
13. Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley NJ. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol. 2005;100 Suppl 1:S5-S21. doi: 10.1111/j.1572-0241.2005.50613_2.x.
14. Corsetti M, Tack J. Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation. United European Gastroenterol J. 2013 Feb;1(1):7-20. doi: 10.1177/2050640612474446.
15. Andresen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S, Foxx-Orenstein A, Kurtz CB, Sharma V, Johnston JM, Currie MG, Zinsmeister AR. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology. 2007 Sep;133(3):761-8. doi: 10.1053/j.gastro.2007.06.067.
16. Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, Eng P, Fox SM, Schneier HA, Kurtz CB, Johnston JM. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012 Nov;107(11):1714-24. doi: 10.1038/ajg.2012.255.
17. Quigley EM, Tack J, Chey WD, Rao SS, Fortea J, Falques M, Diaz C, Shiff SJ, Currie MG, Johnston JM. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther. 2013 Jan;37(1):49-61. doi: 10.1111/apt.12123.
18. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD, Shao JZ, Fitch DA, Baird MJ, Schneier HA, Johnston JM. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012 Nov;107(11):1702-12. doi: 10.1038/ajg.2012.254.
19. Layer P, Stanghellini V. Review article: Linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2014 Feb;39(4):371-84. doi: 10.1111/apt.12604.
20. Fukudo S, Miwa H, Nakajima A, Haruma K, Kosako M, Nakagawa A, Akiho H, Yamaguchi Y, Johnston JM, Currie M, Kinoshita Y. A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan. Neurogastroenterol Motil. 2018 Dec;30(12):e13444. doi: 10.1111/nmo.13444.
21. Yang Y, Fang J, Guo X, Dai N, Shen X, Yang Y, Sun J, Bhandari BR, Reasner DS, Cronin JA, Currie MG, Johnston JM, Zeng P, Montreewasuwat N, Chen GZ, Lim S. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions. J Gastroenterol Hepatol. 2018 May;33(5):980-9. doi: 10.1111/jgh.14086.
22. Rowat A, Graham C, Dennis M. Dehydration in hospital-admitted stroke patients: detection, frequency, and association. Stroke. 2012 Mar;43(3):857-9. doi: 10.1161/STROKEAHA.111.640821.
23. Chow KM, Kwan BC, Szeto CC. Clinical studies of thiazide-induced hyponatremia. J Natl Med Assoc. 2004 Oct;96(10):1305-8.
24. Cersosimo E, Solis-Herrera C, Triplitt C. Inhibition of renal glucose reabsorption as a novel treatment for diabetes patients. J Bras Nefrol. 2014 Jan-Mar;36(1):80-92. doi: 10.5935/0101-2800.20140014.
25. Allegato I. Riassunto Delle Caratteristiche Del Prodotto. Available at: https://ec.europa.eu/health/documents/community-register/2012/20121126124562/anx_124562_it.pdf. Accessed December 15, 2022.
26. Schoenfeld P, Lacy BE, Chey WD, Lembo AJ, Kurtz CB, Reasner DS, Bochenek W, Tripp K, Currie MG, Fox SM, Blakesley RE, OʼDea CR, Omniewski ND, Hall ML. Low-dose linaclotide (72 μg) for chronic ıdiopathic constipation: A 12-week, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2018 Jan;113(1):105-14. doi: 10.1038/ajg.2017.230.
27. Mascarenhas-Saraiva MJ, Mascarenhas-Saraiva M. Effectiveness and tolerability of linaclotide in the treatment of IBS-C in a "real-life" setting: Results from a Portuguese single-center study. Neurogastroenterol Motil. 2019 Feb;31(2):e13508. doi: 10.1111/nmo.13508.
28. Pohl D, Fried M, Lawrance D, Beck E, Hammer HF. Multicentre, non-interventional study of the efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in primary, secondary and tertiary centres: the Alpine study. BMJ Open. 2019 Dec 30;9(12):e025627. doi: 10.1136/bmjopen-2018-025627.
29. Soncini M, Stasi C, Usai Satta P, Milazzo G, Bianco M, Leandro G, Montalbano LM, Muscatiello N, Monica F, Galeazzi F, Bellini M; AIGO. IBS clinical management in Italy: The AIGO survey. Dig Liver Dis. 2019 Jun;51(6):782-9. doi: 10.1016/j.dld.2018.10.006.